The utilization of the tyrosine kinase inhibitor (TKI) sunitinib (Sutent) tremendously improved development-free survival (PFS) in patients with malignant pheochromocytoma and paraganglioma (PPGL), an awfully…
The utilization of the tyrosine kinase inhibitor (TKI) sunitinib (Sutent) tremendously improved development-free survival (PFS) in patients with malignant pheochromocytoma and paraganglioma (PPGL), an awfully…